Results 91 to 100 of about 5,803 (182)

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis [PDF]

, 2018
BACKGROUND & AIMS:We aimed to evaluate the safety and effectiveness of 12 or 24 weeks treatment with ledipasvir and sofosbuvir, with or without ribavirin, in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection ...
Stefan Zeuzem, Michael, Larry, Vainorius, Monika, Lim, Joseph K, Ben-Ari, Ziv, Joseph K. Lim, Norah A. Terrault, Hassan, Mohamed, Lucy Akushevich, Pockros, Paul J, Group, HCV-TARGET Study, Nelson, David R, Paul J. Pockros, Joel Gallant, Terrault, Norah A, Monika Vainorius, Landis, Charles S, Alexander Kuo, David R. Nelson, Shiffman, Mitchell L, Kuo, Alexander, James S. Park, Liapakis, Ann Marie, Michael W. Fried, Park, James S, Mitchell L. Shiffman, Lok, Anna S, Mohamed Hassan, Ziv Ben-Ari, Akushevich, Lucy, Charles S. Landis, Fried, Michael W, Ann Marie Liapakis, Gallant, Joel, Anna S. Lok, Larry Michael, Zeuzem, Stefan   +36 more
core   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

SAGE Open Medicine, 2018
Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or ...
Mete Akin, Osman Cagin Buldukoglu, Haydar Adanir, Inci Suleymanlar, Dinc Dincer, Bulent Yildirim   +5 more
doaj   +1 more source

Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report

Journal of the International Association of Providers of AIDS Care, 2019
This report describes a case of concomitant treatment of advanced diffuse large B-cell lymphoma with chemoimmunotherapy along with direct-acting antivirals for hepatitis C virus in a patient coinfected with HIV.
Alyssa Gallipani PharmD, BCACP, Agnes Cha PharmD, AAHIVP, BCACP, Leonard Berkowitz MD, Anjali Bakshi MD   +3 more
doaj   +1 more source

Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products

, 2017
Sofosbuvir and ledipasvir are the first drugs in a combination pill to treat chronic hepatitis C virus. Simple, sensitive, and rapid spectrophotometric methods are presented for the determination of sofosbuvir and ledipasvir in their combined dosage form.
Mohamed R El-Ghobashy, Nisreen F Abo-Talib, Marwa H Tammam   +2 more
core   +1 more source

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
Kwo, Paul Y., Agarwal, Kosh, Muir, Andrew J., Buti, Maria, Symonds, William T., Mo, Hongmei, Afdhal, Nezam, Jacobson, Ira M., Marcellin, Patrick, Pang, Philip S., Foster, Graham R., Mangia, Alessandra, Chojkier, Mario, Ding, Xiao, Romero Gomez, Manuel, Yang, Jenny C., Zarski, Jean Pierre, Bräu, Norbert, Gitlin, Norman, Puoti, Massimo, Buggisch, Peter, Forns, Xavier, Subramanian, G.Mani, Zeuzem, Stefan, McHutchison, John G.   +24 more
core  

Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient

, 2017
Here we describe the case of a HIV-positive patient with acute hepatitis C virus reinfection, who was successfully treated with an interferon-free regimen of ledipasvir ...
Giacomelli, Andrea, Sollima, Salvatore, Milazzo, Laura, Binda, Francesca, Antinori, Spinello, Torre, Alessandro   +5 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF UV- VISIBLE SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF SOFOSBUVIR AND LEDIPASVIR IN PHARMACEUTICAL API AND ITS FORMULATION

, 2018
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Sofosbuvir and Ledipasvir in its active pharmaceutical ingredient (API) form
N. Mohana Vamsi 1 *, Dr. Y. Padmanabha Reddy 2, Dr. R. Vijay Kumar 3
core   +1 more source

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C

Hepatic Medicine: Evidence and Research, 2017
Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV)
Naylor PH, Mutchnick M
doaj  

Ledipasvir [PDF]

, 2020
openaire   +1 more source